Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections

Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections

By: Ankit Mahadevia, MD – CEO of Spero Therapeutics January 9th, 2020 Against a steady drumbeat of alarmist rhetoric in the lay press regarding infectious disease, at Spero we remain focused on developing our first-in-class pipeline of oral agents to treat what we believe to be the two largest infectious disease market opportunities:  complicated urinary tract infections […]

New Options for Patients: New Preliminary Clinical Data on SPR720 and Our Stepwise Plan to Explore the Broad Potential of SPR720 in NTM

By:  David Melnick, MD – Chief Medical Officer of Spero Therapeutics December 5, 2019 We recently announced positive preliminary, blinded data on SPR720 that we believe supports the further development of SPR720 as an oral agent for the treatment of NTM pulmonary disease.  The data released: Identify a dose range for SPR720 to explore in […]

Non-tuberculous Mycobacterial Disease: The Unmet Need and a Possible New Solution with SPR720

By: Ankit Mahadevia, MD  and Cristina Larkin   November 5th, 2018 Non-tuberculous mycobacterial (NTM) disease is a rare, chronic infectious disease with limited treatment options that has a devastating impact on patients and their families.  We at Spero are excited to announce that SPR720, our oral, broad-spectrum compound for NTM, will be entering clinical development in early 2019. SPR720 […]